Sundry Photography/iStock Editorial via Getty Images
- Tandem Diabetes Care (NASDAQ:TNDM) will work with Abbott Laboratories (NYSE:ABT) that will combine the former’s insulin delivery systems with the latter’s under development dual glucose-ketone sensor.
- Abbott’s sensor can “detect early ketone rise to avoid life-threatening diabetic ketoacidosis,” according to a news release.
- “Integrating our advanced insulin delivery systems with Abbott’s future glucose-ketone sensor has the potential to help empower people with diabetes to take faster, more informed action to protect their health and improve outcomes,” Tandem CEO John Sheridan said.
More on Tandem Diabetes Care, Abbott Laboratories
- Tandem Diabetes Care: A Barbell Bet On A High-Stakes Turnaround
- Abbott Laboratories: Why Wall Street’s Skepticism Misses The Real Story
- The Growth Of Medical Devices Needs To Continue In Order To Invest In Abbott
- Abbott gets FDA nod for Tendyne valve for mitral valve disease
- Tandem to pay Roche $36M in patent dispute settlement